Topical Treatments for Seborrheic Keratosis: a Systematic Review
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Skin Lesions in Diabetic Patients
Rev Saúde Pública 2005;39(4) 1 www.fsp.usp.br/rsp Skin lesions in diabetic patients N T Foss, D P Polon, M H Takada, M C Foss-Freitas and M C Foss Departamento de Clínica Médica. Faculdade de Medicina de Ribeirão Preto. Universidade de São Paulo. Ribeirão Preto, SP, Brasil Keywords Abstract Skin diseases. Dermatomycoses. Diabetes mellitus. Metabolic control. Objective It is yet unknown the relationship between diabetes and determinants or triggering factors of skin lesions in diabetic patients. The purpose of the present study was to investigate the presence of unreported skin lesions in diabetic patients and their relationship with metabolic control of diabetes. Methods A total of 403 diabetic patients, 31% type 1 and 69% type 2, underwent dermatological examination in an outpatient clinic of a university hospital. The endocrine-metabolic evaluation was carried out by an endocrinologist followed by the dermatological evaluation by a dermatologist. The metabolic control of 136 patients was evaluated using glycated hemoglobin. Results High number of dermophytosis (82.6%) followed by different types of skin lesions such as acne and actinic degeneration (66.7%), pyoderma (5%), cutaneous tumors (3%) and necrobiosis lipoidic (1%) were found. Among the most common skin lesions in diabetic patients, confirmed by histopathology, there were seen necrobiosis lipoidic (2 cases, 0.4%), diabetic dermopathy (5 cases, 1.2%) and foot ulcerations (3 cases, 0.7%). Glycated hemoglobin was 7.2% in both type 1 and 2 patients with adequate metabolic control and 11.9% and 12.7% in type 1 and 2 diabetic patients, respectively, with inadequate metabolic controls. -
A Review of the Evidence for and Against a Role for Mast Cells in Cutaneous Scarring and Fibrosis
International Journal of Molecular Sciences Review A Review of the Evidence for and against a Role for Mast Cells in Cutaneous Scarring and Fibrosis Traci A. Wilgus 1,*, Sara Ud-Din 2 and Ardeshir Bayat 2,3 1 Department of Pathology, Ohio State University, Columbus, OH 43210, USA 2 Centre for Dermatology Research, NIHR Manchester Biomedical Research Centre, Plastic and Reconstructive Surgery Research, University of Manchester, Manchester M13 9PT, UK; [email protected] (S.U.-D.); [email protected] (A.B.) 3 MRC-SA Wound Healing Unit, Division of Dermatology, University of Cape Town, Observatory, Cape Town 7945, South Africa * Correspondence: [email protected]; Tel.: +1-614-366-8526 Received: 1 October 2020; Accepted: 12 December 2020; Published: 18 December 2020 Abstract: Scars are generated in mature skin as a result of the normal repair process, but the replacement of normal tissue with scar tissue can lead to biomechanical and functional deficiencies in the skin as well as psychological and social issues for patients that negatively affect quality of life. Abnormal scars, such as hypertrophic scars and keloids, and cutaneous fibrosis that develops in diseases such as systemic sclerosis and graft-versus-host disease can be even more challenging for patients. There is a large body of literature suggesting that inflammation promotes the deposition of scar tissue by fibroblasts. Mast cells represent one inflammatory cell type in particular that has been implicated in skin scarring and fibrosis. Most published studies in this area support a pro-fibrotic role for mast cells in the skin, as many mast cell-derived mediators stimulate fibroblast activity and studies generally indicate higher numbers of mast cells and/or mast cell activation in scars and fibrotic skin. -
COVID-19 Mrna Pfizer- Biontech Vaccine Analysis Print
COVID-19 mRNA Pfizer- BioNTech Vaccine Analysis Print All UK spontaneous reports received between 9/12/20 and 22/09/21 for mRNA Pfizer/BioNTech vaccine. A report of a suspected ADR to the Yellow Card scheme does not necessarily mean that it was caused by the vaccine, only that the reporter has a suspicion it may have. Underlying or previously undiagnosed illness unrelated to vaccination can also be factors in such reports. The relative number and nature of reports should therefore not be used to compare the safety of the different vaccines. All reports are kept under continual review in order to identify possible new risks. Report Run Date: 24-Sep-2021, Page 1 Case Series Drug Analysis Print Name: COVID-19 mRNA Pfizer- BioNTech vaccine analysis print Report Run Date: 24-Sep-2021 Data Lock Date: 22-Sep-2021 18:30:09 MedDRA Version: MedDRA 24.0 Reaction Name Total Fatal Blood disorders Anaemia deficiencies Anaemia folate deficiency 1 0 Anaemia vitamin B12 deficiency 2 0 Deficiency anaemia 1 0 Iron deficiency anaemia 6 0 Anaemias NEC Anaemia 97 0 Anaemia macrocytic 1 0 Anaemia megaloblastic 1 0 Autoimmune anaemia 2 0 Blood loss anaemia 1 0 Microcytic anaemia 1 0 Anaemias haemolytic NEC Coombs negative haemolytic anaemia 1 0 Haemolytic anaemia 6 0 Anaemias haemolytic immune Autoimmune haemolytic anaemia 9 0 Anaemias haemolytic mechanical factor Microangiopathic haemolytic anaemia 1 0 Bleeding tendencies Haemorrhagic diathesis 1 0 Increased tendency to bruise 35 0 Spontaneous haematoma 2 0 Coagulation factor deficiencies Acquired haemophilia -
Fundamentals of Dermatology Describing Rashes and Lesions
Dermatology for the Non-Dermatologist May 30 – June 3, 2018 - 1 - Fundamentals of Dermatology Describing Rashes and Lesions History remains ESSENTIAL to establish diagnosis – duration, treatments, prior history of skin conditions, drug use, systemic illness, etc., etc. Historical characteristics of lesions and rashes are also key elements of the description. Painful vs. painless? Pruritic? Burning sensation? Key descriptive elements – 1- definition and morphology of the lesion, 2- location and the extent of the disease. DEFINITIONS: Atrophy: Thinning of the epidermis and/or dermis causing a shiny appearance or fine wrinkling and/or depression of the skin (common causes: steroids, sudden weight gain, “stretch marks”) Bulla: Circumscribed superficial collection of fluid below or within the epidermis > 5mm (if <5mm vesicle), may be formed by the coalescence of vesicles (blister) Burrow: A linear, “threadlike” elevation of the skin, typically a few millimeters long. (scabies) Comedo: A plugged sebaceous follicle, such as closed (whitehead) & open comedones (blackhead) in acne Crust: Dried residue of serum, blood or pus (scab) Cyst: A circumscribed, usually slightly compressible, round, walled lesion, below the epidermis, may be filled with fluid or semi-solid material (sebaceous cyst, cystic acne) Dermatitis: nonspecific term for inflammation of the skin (many possible causes); may be a specific condition, e.g. atopic dermatitis Eczema: a generic term for acute or chronic inflammatory conditions of the skin. Typically appears erythematous, -
A Curious Keloid of the Penis
384 Letters to the Editor A Curious Keloid of the Penis Antonio Mastrolorenzo, Anna Lisa Rapaccini, Luana Tiradritti and Giuliano Zuccati Department of Dermatological Sciences, University of Florence, via Degli Alfani, 37, IT-50121 Firenze, Italy. E-mail:[email protected] Accepted April 11, 2003. Sir, performed and the histopathological analysis of the Keloids of the genitalia and penis are rare despite specimen revealed irregular and thick collagen bundles frequent surgery in this area. A careful review of the characteristic of keloid. There was no evidence of literature revealed only a few cases reported since granuloma in tissue sections to suggest a possible Browne’s statement in 1949 that the skin of the penis infectious cause. The scar was treated for the next 3 ‘‘never forms a keloid’’ (1), and Crockett’s research months with topical use of fluocinolone acetonide gel attempting to classify the susceptibility of different areas twice a day. A 12-month follow-up showed that the of the body to keloid formation and not finding any cases wound healed perfectly, leaving a small elevated, firm scar affecting genitalia in a survey of 250 Sudanese natives (2). but without itching, redness or any other sign of keloid The aim of this report is to document a case that has recurrence. In the last 6 months there was no appreciable resulted from such a common treatment as diathermy for change in the lesion. genital warts. DISCUSSION CASE REPORT We report what we believe is the tenth documented case A 32-year-old Negro man was referred to our department of keloid of the penis. -
Cryosurgery Using the Cryopen®
Cryosurgery using the CryoPen® FAQ CRYOSURGERY What is cryosurgery? Cryosurgery is a procedure that uses extreme cold to destroy tissue. How can my practice benefit from using cryosurgery in my practice? Cryosurgery in the office offers an excellent modality for eliminating referral time while creating an added source of revenue. How can my patients benefit from having cryosurgery in my practice? Patients will appreciate the efficient use of their time and decreased cost of services by avoiding secondary visits to specialists. By keeping the procedure in house, patients will put a greater value on your practice. How is cryosurgery better than other methods of removing skin lesions? Cryosurgery requires no anesthesia and has less scarring than other techniques of skin lesion removal with minimal post-op care. What is the mechanism of cell destruction in cryosurgery? Cell destruction occurs when a cell is rapidly brought down to a very low temperature. When these two criteria are met (varies with cell type), ice crystals form, destroying the cell organelles and protein matrixes. Water then rushes into the surrounding area causing a blister and a disruption of the local blood supply. Cytologic evidence of cell destruction can be seen as soon as two hours after the procedure. What types of lesions are appropriate to freeze? Almost any unwanted skin lesions are appropriate such as warts, moles, actinic keratosis, seborrheic keratosis, keloids, lentigos, dermatofibromas, and hemangiomas to just name a few. In most practices, over 90% of unwanted lesions encountered are amenable to using cryosurgery. What types of lesions are not appropriate to freeze? All Melanomas and Recurrent Basal Cell Carcinomas are contraindicated for cryosurgery. -
Nodular Morphea
Case Report Dermatology 2009;218:63–66 Received: July 13, 2008 DOI: 10.1159/000173976 Accepted: July 23, 2008 Published online: November 13, 2008 Nodular Morphea a b c F. Kauer J.C. Simon M. Sticherling a b Department of Dermatology and Venerology, Vivantes Klinikum Neukölln, Berlin , Department of Dermatology, c Venerology and Allergology, University of Leipzig, Leipzig , and Department of Dermatology, Venerology and Allergology, University of Erlangen, Erlangen , Germany Key Words can range in size from 2 mm to 4–5 cm, flamed skin that is already involved in an -Scleroderma ؒ Keloid ؒ Hypertrophic scar ؒ usually appear spontaneously and tend to active fibrotic process inherent to the dis Morphea involve the trunk and upper extremities. ease in those patients who are genetically A linear presentation has also been de- predisposed to keloid development, or at scribed. The literature on this topic is con- sites of the skin that show a high predilec- Abstract fusing because the terms ‘nodular sclero- tion for keloid formation, such as the trunk Scleroderma may present as being strictly derma’ and ‘keloidal scleroderma’ are used [6, 7] . limited to the skin, as in morphea, or within interchangeably even though there is a a multiorgan disease, as in systemic sclero- great degree of variability in the histologi- sis. Accordingly, cutaneous manifestations cal findings of these nodules [4] . In con- C a s e R e p o r t vary clinically. In nodular or keloidal sclero- trast, other authors stress that the cutane- derma, patients develop lesions that are ous manifestations may vary clinically, but Medical History clinically indistinguishable from a keloid; all share the same histopathological pat- A 16-year-old girl presented with mul- however, the histopathological findings are tern of both morphea/scleroderma and ke- tiple progressive morpheic skin lesions more variable. -
Nodular Scleroderma in a Patient with Chronic Hepatitis C Virus Infection: a Coexistent Or Causal Infection?
Nodular Scleroderma in a Patient With Chronic Hepatitis C Virus Infection: A Coexistent or Causal Infection? Chayada Kokpol, MD; Emily Y. Chu, MD, PhD; Suthinee Rutnin, MD PRactice Points Nodular scleroderma is a rare form of cutaneous scleroderma that can occur in association with systemic scleroderma or localized morphea. The clinical features are characterized by solitary or multiple, firm, long-lasting papules or nodules on the neck, upper trunk, and proximal extremities. The pathogenesis is still unclear. Some reports have suggested that matricellularcopy protein and growth factor, acid-fast bacteria, organic solvents, or the hepatitis C virus may be involved. not Nodular scleroderma is a rare form of scleroderma neck and trunk that had been present for 2 years. that may occur systemically or locally. The patho-DoThree years prior to presentation she had been diag- genesis of this variant is unknown. We report the nosed with systemic sclerosis (SSc) after develop- case of a 63-year-old woman with systemic sclero- ing progressive diffuse cutaneous sclerosis, Raynaud derma and chronic hepatitis C virus (HCV) infec- phenomenon with digital pitted scarring, esophageal tion who had numerous papules and nodules on dysmotility, myositis, pericardial effusion, and inter- the neck and trunk. Skin biopsies from her lesions stitial lung disease. Serologic test results were posi- revealed characteristic findings of scleroderma. tive for anti-Scl-70 antibodies. Antinuclear antibody This case not only depicts the rare entity of nodular test results were negative for anti–double-stranded scleroderma but demonstratesCUTIS the association of DNA, anti-nRNP, anti-Ro/La, anti-Sm, and anti-Jo-1 HCV infection with systemic autoimmune diseases antibodies. -
What to Expect Following Cryosurgery “Freezing”
What to Expect Following CryoSurgery “Freezing” What is Cryosurgery? Cryosurgery is a technique for removing skin lesions that primarily involve the surface of the skin, such as warts, seborrheic keratosis, or actinic keratosis. It is a quick method of removing the lesions with minimal scarring. The liquid nitrogen needs to be applied long enough to freeze the affected skin. By freezing the skin, a blister is created underneath the lesion. Ideally, as the new skin forms underneath the blister, the abnormal skin on the roof of the blister peels off. Occasionally if the lesion is very thick (such as a large wart), only the surface is blistered off. The base or residual lesion may need to be frozen at another visit. What to Expect Over the Next Few Weeks? During Treatment – Area being treated will sting, burn and then possibly itch. Immediately After Treatment – Area will be red sore and swollen. Next Day- Blister or blood blister has formed, tenderness starts to subside. Apply a Band-Aid if necessary. 7 Days- Surface is dark red/brown and scab-like. Apply Vaseline or an antibacterial ointment if necessary. 2 to 4 Weeks- The surface starts to peel off. This may be encouraged gently during bathing, when the scab is softened. No makeup should be applied until area is fully healed. How to Take care of the Skin after Cryosurgery A Band-Aid can be used for larger blisters or blisters in areas that are more likely to be traumatized- such as fingers and toes. If the area becomes dry or crusted, an ointment (Vaseline, Aquaphor) can also be applied. -
Treatment Or Removal of Benign Skin Lesions
Treatment or Removal of Benign Skin Lesions Date of Origin: 10/26/2016 Last Review Date: 03/24/2021 Effective Date: 04/01/2021 Dates Reviewed: 10/2016, 10/2017, 10/2018, 04/2019, 10/2019, 01/2020, 03/2020, 03/2021 Developed By: Medical Necessity Criteria Committee I. Description Individuals may acquire a multitude of benign skin lesions over the course of a lifetime. Most benign skin lesions are diagnosed on the basis of clinical appearance and history. If the diagnosis of a lesion is uncertain, or if a lesion has exhibited unexpected changes in appearance or symptoms, a diagnostic procedure (eg, biopsy, excision) is indicated to confirm the diagnosis. The treatment of benign skin lesions consists of destruction or removal by any of a wide variety of techniques. The removal of a skin lesion can range from a simple biopsy, scraping or shaving of the lesion, to a radical excision that may heal on its own, be closed with sutures (stitches) or require reconstructive techniques involving skin grafts or flaps. Laser, cautery or liquid nitrogen may also be used to remove benign skin lesions. When it is uncertain as to whether or not a lesion is cancerous, excision and laboratory (microscopic) examination is usually necessary. II. Criteria: CWQI HCS-0184A Note: **If request is for treatment or removal of warts, medical necessity review is not required** A. Moda Health will cover the treatment and removal of 1 or more of the following benign skin lesions: a. Treatment or removal of actinic keratosis (pre-malignant skin lesions due to sun exposure) is considered medically necessary with 1 or more of the following procedures: i. -
Lumps & Bumps: Approach to Common Dermatologic Neoplasms
Case-Based Approach to Common Dermatologic Neoplasms Patrick Retterbush, MD, FAAD Mohs Surgery & Dermatologic Oncology Associate Member of the American College of Mohs Surgery Private Practice: Lockman Dermatology January 27th 2018 Disclosure of Relevant Financial Relationships • I do not have any relevant financial relationships, commercial interests, and/or conflicts of interest regarding the content of this presentation. Goals/Objectives • Recognize common benign growths • Recognize common malignant growths • Useful clues & examination for evaluating melanocytic nevi and when to be concerned for melanoma/atypical moles • How to perform a basic skin biopsy and which method/type to choose • Basic treatment/when to refer Key Questions & Physical Examination Findings for a Growth History Physical Examination • How long has the lesion been • Describing a growth present? – flat or raised? • flat – macule (<1cm) or patch (>1cm) – years, months, weeks • raised – papule (<1cm) or plaque (>1cm) – nodule if deep (majority of lesion in • Has it changed? dermis/SQ) – Size – secondary descriptive features • scaly (hyperkeratosis, retention of strateum – Shape corneum) – Color • crusty (dried serum, blood, or pus on surface) • eroded or ulcerated (partial vs. full thickness – Symptoms – pain, bleeding, itch? epidermal loss) – Over what time frame? • color (skin colored, red, pigmented, pearly) • feel (hard or soft, mobile or fixed) • PMH: • size: i.e. 6 x 4mm – prior skin cancers • Look at the rest of the skin/region of skin • SCC/BCCs vs. melanoma -
Common Terminology Criteria for Adverse Events
Common Terminology Criteria for Adverse Events Version 3.0 Index Cancer Therapy Evaluation Program NATIONAL INSTITUTES OF HEALTH National Cancer Institute http://ctep.cancer.gov/ 10/22/2003 Public Health Service Cancer Therapy Evaluation Program National Institutes of Health National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) - Index Terms Report Bethesda, Maryland 20892 -- A -- abdomen ENDOCRINE HEPATOBILIARY/PANCREAS Adrenal insufficiency 17 Liver dysfunction/failure (clinical) 34 GASTROINTESTINAL Pancreatitis 34 Colitis 19 PAIN Distension/bloating, abdominal 20 Pain --Select 55 Enteritis (inflammation of the small bowel) 21 VASCULAR Fistula, GI --Select 22 Portal vein flow 70 Typhlitis (cecal inflammation) 27 HEMORRHAGE/BLEEDING abducens Hemorrhage, GI --Select 31 See: CN VI HEPATOBILIARY/PANCREAS abnormal Pancreatitis 34 BLOOD/BONE MARROW INFECTION Myelodysplasia 4 Colitis, infectious (e.g., Clostridium difficile) 35 CONSTITUTIONAL SYMPTOMS Infection (documented clinically or microbiologically) with 35 Odor (patient odor) 11 Grade 3 or 4 neutrophils (ANC <1.0 x 10e9/L) --Select Infection with normal ANC or Grade 1 or 2 neutrophils -- 35 ENDOCRINE Select Neuroendocrine: 17 Infection with unknown ANC --Select 36 ADH secretion abnormality (e.g., SIADH or low ADH) Neuroendocrine: 17 MUSCULOSKELETAL/SOFT TISSUE gonadotropin secretion abnormality Soft tissue necrosis --Select 46 Neuroendocrine: 17 PAIN growth hormone secretion abnormality Neuroendocrine: 17 Pain --Select 55 prolactin hormone secretion abnormality